Evidence map›Paper›PMID 38808676›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects.

Adrienne Biskaduros, Lidia Glodzik, Leslie A Saint Louis, Henry Rusinek, Elizabeth Pirraglia, Ricardo Osorio, Tracy Butler, Yi Li, Ke Xi, Emily Tanzi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adrienne BiskadurosBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0003-2165-9480
Lidia GlodzikBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Leslie A Saint LouisBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Henry RusinekDepartment of Radiology, New York University Grossman School of Medicine, New York, New York, USA.
Elizabeth PirragliaDepartment of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
Ricardo OsorioDepartment of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
Tracy ButlerBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Yi LiBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Ke XiBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Emily TanziBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Patrick HarveyBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden.
Mony J de LeonBrain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.

Funding

PREDICTORS OF COGNITIVE DECLINE IN NORMAL AGINGR01AG012101 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DE LEON, MONY J., RUSINEK, HENRY · 1993 to 2015
$6.7M
Blood Pressure, Cerebral Perfusion & Cognitive Outcome In Hypertension.R01HL111724 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLODZIK, LIDIA · 2012 to 2025
$6.6M
Biomarkers in Early Alzheimer's Disease (AD).R01AG022374 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DE LEON, MONY J., RUSINEK, HENRY · 2004 to 2015
$5.2M
Sleep Aging and Risk for Alzheimer's disease-Resubmission-1R01AG056031 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSORIO, RICARDO S · 2018 to 2022
$4.4M
PET Measures of CSF Clearance in Preclinical Alzheimer's DiseaseRF1AG057570 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE LEON, MONY J. · 2017 to 2017
$4.1M
Hypertension, brain clearance and markers of neurodegenerationR01NS104364 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLODZIK, LIDIA · 2018 to 2022
$3.7M
CSF Clearance with 11C-Butanol PET Predicts Amyloid DepositionR56AG058913 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE LEON, MONY J., RUSINEK, HENRY · 2018 to 2018
$861k
NHLBI NIH HHS R01 HL111724NIA NIH HHS R01 AG012101NIA NIH HHS R01 AG022374NIA NIH HHS R01 AG056031NIA NIH HHS R56 AG058913NIA NIH HHS RF1 AG057570NIH HHS AG022374NIH HHS AG05603NIH HHS AG057570NIH HHS AG058913NIH HHS AG12101NIH HHS HL111724NIH HHS NS104364NINDS NIH HHS R01 NS104364
6 · The paper itself

Abstract

introductionWe examined whether hypertension (HTN) was associated with Alzheimer's disease-related biomarkers in cerebrospinal fluid (CSF) and how changes in blood pressure (BP) related to changes in CSF biomarkers over time.

methodsA longitudinal observation of cognitively healthy normotensive subjects (n = 134, BP < 140/90, with no antihypertensive medication), controlled HTN (n = 36, BP < 140/90, taking antihypertensive medication), and 35 subjects with uncontrolled HTN (BP ≥ 140/90). The follow-up range was 0.5to15.6 years.

resultsTotal tau (T-tau) and phospho-tau181 (P-tau 181) increased in all but controlled HTN subjects (group×time interaction: p < 0.05 for both), but no significant Aβ42 changes were seen. Significant BP reduction was observed in uncontrolled HTN, and it was related to increase in T-tau (p = 0.001) and P-tau 181 (p < 0.001). DISCUSSION: Longitudinal increases in T-tau and P-tau 181 were observed in most subjects; however, only uncontrolled HTN had both markers increase alongside BP reductions. We speculate cumulative vascular injury renders the brain susceptible to relative hypoperfusion with BP reduction. HIGHLIGHTS: Over the course of the study, participants with uncontrolled HTN at baseline showed greater accumulation of CSF total tau and phospho-tau181 (P-tau 181) than subjects with normal BP or with controlled HTN. In the group with uncontrolled HTN, increases in total tau and P-tau 181 coincided with reduction in BP. We believe this highlights the role of HTN in vascular injury and suggests decline in cerebral perfusion resulting in increased biomarker concentrations in CSF. Medication use was the main factor differentiating controlled from uncontrolled HTN, indicating that earlier treatment was beneficial for preventing accumulations of pathology.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersBlood PressureHypertensiontau ProteinsAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedPeptide FragmentsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseCSF biomarkersneurodegeneration

Identifiers

PMID38808676
PMCPMC11247669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.